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Abstract
Background: Our objectives were to examine temporal changes in HbA1c and lipid levels over a 10-year period and to 
identify predictors of metabolic control in a longitudinal patient cohort.
Methods: We identified all adults within our hospital network with T2DM who had HbA1c's measured in both 1996 
and 2006 (longitudinal cohort). For patients with no data in 2006, we used hospital and social security records to 
distinguish patients lost to follow-up from those who died after 1996. We compared characteristics of the 3 baseline 
cohorts (longitudinal, lost to f/u, died) and examined metabolic trends in the longitudinal cohort.
Results: Of the 4944 patients with HbA1c measured in 1996, 1772 (36%) had an HbA1c measured in 2006, 1296 (26%) 
were lost to follow-up, and 1876 (38%) had died by 2006. In the longitudinal cohort, mean HbA1c decreased by 0.4 ± 
1.8% over the ten-year span (from 8.2% ± 1.7% to 7.8% ± 1.4%) and mean total cholesterol decreased by 49.3 (± 46.5) 
mg/dL. In a multivariate model, independent predictors of HbA1c decline included older age (OR 1.41 per decade, 95% 
CI: 1.3-1.6, p < 0.001), baseline HbA1c (OR 2.9 per 1% increment, 2.6 - 3.2, p < 0.001), and speaking English (OR 2.1, 1.4-
3.1, p < 0.001).
Conclusions: Despite having had diabetes for an additional 10 years, patients in our longitudinal cohort had better 
glycemic and cholesterol control in 2006 than 1996. Greatest improvements occurred in patients with the highest 
levels in the baseline year.
Background
As the incidence of diabetes continues to increase in the
United States, it has become increasingly important to
understand trends in progression of the disease over time
[1]. Type 2 diabetes (T2D) is seen as an inexorably pro-
g r e s s i v e  d i s e a s e ,  w i t h  b e t a  c e l l  f a i l u r e  a n d  i n c r e a s i n g
peripheral insulin resistance leading to worsening glyce-
mic control, microvascular complications such as retin-
opathy and peripheral neuropathy, and significant
macrovascular morbidity [2-4]. Medical therapy, when
applied effectively, can prevent or delay the development
of long-term complications, mediated largely through
improved control of blood pressure, glycemia, and lipids
[3,5,6].
Several cross-sectional US national surveys have pro-
vided important population-level data on diabetes preva-
lence and metabolic control over time. Data from the
National Health and Nutritional Examination Survey
(NHANES), for example, have confirmed an increasing
diabetes prevalence, increasing obesity among patients
with diabetes, and an apparent trend towards improved
metabolic control after years of worsening [7-10]. How-
ever, interpretation of these trends is confounded by
changes in US demographics and changes in screening
criteria over the past decade. One study from the
National Health Interview Survey, for example, found
that despite significant increases in the diabetes popula-
tion total each year, the mean age for patients with diabe-
tes remained constant over an 8 year period [11].
Longitudinal studies of defined patient populations,
conversely, allow the identification of actual trends in
metabolic control over time and can identify individual-
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level predictors of worsening or improved glycemic con-
trol over time. We used records from a large hospital net-
work to examine trends in both glycemic and lipid
control over a 10-year span. We sought to determine
whether changes in care practices would outweigh the
impact of ten years of disease progression on glycemic
and lipid control in a "real-world" cohort of patients with
type 2 diabetes.
Methods
Setting and Patients
We used an electronic clinical data query to identify all
adults with type 2 diabetes (T2D) receiving outpatient
care at one of the 12 outpatient practices affiliated with
Massachusetts General Hospital (MGH) in 1996. T2D
was defined as 2 outpatient encounters or 1 inpatient
encounter with T2D billing code (250.xx) during 1996 or
an HbA1c > 7% prior to 1996. To further refine our T2D
population, we excluded patients < 35 years of age and
patients with "Type 1" modifiers in their electronic medi-
cal record (EMR) problem lists or ICD-9 billing codes.
We grouped the 4944 eligible patients into 3 cohorts: 1)
the longitudinal cohort (patients who had at least one
HbA1c assay performed in both 1996 and 2006); 2)
patients who died before 2006, and 3) the lost to follow up
cohort (the remaining patients with no 2006 data and no
record of death). The study was approved by the Massa-
chusetts General Hospital/Partners Health Care System
Institutional Review Board.
Clinical Variables
We used a combination of billing, laboratory, EMR, and
appointment data sources to collect the following demo-
graphic and clinical data: age, gender, race, insurance sta-
tus, primary language, HbA1c results and number of
tests, number of outpatient visits, lipid results, and creati-
nine results. Vital status was determined using both hos-
pital records and Social Security Administration's Death
Master File [12].
Because the electronically-available data available for
the overall cohort did not include the more detailed clini-
cal information available from physician narrative prog-
ress notes in 1996, we also conducted two structured
chart review analyses to address two secondary ques-
tions: 1) Among patients with very poor glycemic control
in 1996 (HbA1c ≥ 11.5%, n = 152), did patients in the lon-
gitudinal cohort (n = 69) differ significantly from patients
who were lost to follow-up (n = 83) in terms of medical
and psychiatric comorbidity, substance abuse, or primary
language spoken? And, 2) Among patients with moder-
ately poor glycemic control in 1996, were patients who
improved over the 10-year period more likely to receive
insulin than patients who worsened? To address this sec-
ond question, we conducted a 1:1 case-control analysis
among the longitudinal cohort of patients with HbA1c
levels between 8.0 and 9.0% in 1996 (n = 394) by ran-
domly selecting 50 patients whose HbA1c was at least 1%
lower in 2006 (cases) and 50 patients whose HbA1c was
at least 1% higher in 2006 (controls). These patients were
matched by age and gender.
The HbA1c results were obtained using a high-perfor-
mance liquid chromatography method that has been
described previously [9,13,14]. This assay serves as one of
the primary reference laboratory methods for the
National Glycohemoglobin Standardization Program and
has inter- and intra-assay coefficients of variation <2.5%.
Long-term drift is prevented by the use of long-term con-
trols. Total plasma cholesterol and plasma triglyceride
levels were measured enzymatically [15], high-density
lipoprotein fraction was measured after precipitation of
low-density, and very low-density lipoproteins were mea-
sured using dextran sulfate-magnesium [16]. We esti-
mated LDL cholesterol levels indirectly using the
Friedewald formula for patients with plasma triglyceride
levels <400 mg/dL [17].
Statistical Analysis
We compared the baseline characteristics of the 3 cohorts
using analysis of variance and t-tests for continuous data
and chi-square tests for categorical variables. For the lon-
gitudinal cohort, we examined individual trends in
HbA1c and lipid control between 1996 and 2006. We sep-
arately modeled predictors of worsened glycemic control
and worsened cholesterol control using multivariate
regression modeling after assessing correlations between
predictor variables. For the two chart review analyses, we
used chi-square tests to compare proportions and report
odds ratios. SAS (SAS v 9.1, Cary, North Carolina) was
used for all analyses.
Results
Patient Characteristics
Of the 4944 eligible patients, 1772 (35.8%) had HbA1c
assays performed at MGH in both 1996 and 2006; 1296
(26.2%) were lost to follow-up by 2006; and 1876 (37.9%)
died (Table 1). The mean age for all eligible patients in
1996 was 60.0 (± 16.9) years, 47.9% were women, 23.4%
were non-white, and 12.3% were non-English speaking.
The mean HbA1c in 1996 was 8.3% (± 1.8).
The three cohorts varied significantly at baseline by
age, sex, race/ethnicity, language, and HbA1c levels
(Table 1). Patients who died in the intervening decade
were more than a decade older (mean age 70.6 ± 10.75
years) than the other 2 cohorts (p < 0.001 for either com-
parison). Compared to the longitudinal cohort, the lost to
follow-up cohort had a slightly higher mean HbA1c (8.4 ±
1.9% vs. 8.2 ± 1.7%, p = 0.002) and fewer HbA1c tests (1.8
± 1.1 vs. 2.1 ± 1.1, p < 0.001) in 1996.Blumenthal et al. BMC Health Services Research 2010, 10:158
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Glycemic Control in the Longitudinal Cohort
The mean HbA1c decreased by 0.4 ± 1.8% (from 8.2% ±
1.7% to 7.8% ± 1.4% between 1996 and 2006) among
patients in the longitudinal cohort with the majority
(58.6%) having improved their glycemic control over this
10-year period. The group with the poorest glycemic con-
trol in 1996 experienced the biggest decreases in their
HbA1c over the 10 years, while the patients with rela-
tively good glycemic control in 1996 (HbA1c <= 8%)
tended to have increased HbA1c by 2006 (Figure 1). The
proportion of patients with HbA1c < 7.0% increased from
23.4% to 26.9% over the ten-year span (p = 0.02).
Using logistic regression, we found that higher baseline
age (OR 1.41 per decade, 95% CI: 1.3-1.6, p < 0.001),
higher baseline HbA1c (OR 2.9 per 1% higher HbA1c, 2.6
- 3.2, p < 0.001), and speaking English (OR 2.1, 1.4-3.1, p <
0.001) each independently predicted HbA1c improve-
ment over the next 10 years (Table 2), while race, gender,
creatinine and lipid levels, testing and visit frequency did
not. A linear regression model with just these three cova-
riates explained 51% of the variability in HbA1c change
over time (adjusted R-squared 0.51).
Figure 2 presents the mean HbA1c per year from 1996
to 2005 for the longitudinal group. This figure also shows
mean annual HbA1c levels for the lost to follow-up
cohort for as many years as available for each patient.
Although baseline HbA1c remained slightly higher from
baseline onward in this second group, the improvement
trend follows a similar pattern as the longitudinal cohort.
Dyslipidemia in the Longitudinal Cohort
Total cholesterol results in both 1996 and 2006 were
available for 1131 patients (63.8%) in the longitudinal
cohort. In this subset of patients, 89.1% of patients had a
decrease in total cholesterol and the mean total choles-
terol decreased by an average of 49.3 (± 46.5) mg/dL
between 1996 and 2006. The prevalence of LDL testing
increased from 61.5% in 1996 to 84.1% in 2006. Of the
945 patients with LDL measurements in both periods,
mean levels declined 54.0 (± 37.7) mg/dL, while HDL lev-
els among patients measured in both periods (n = 1131)
increased by 11.6 (± 11.4) mg/dL. Independently signifi-
cant baseline predictors of total cholesterol improvement
over 10 years included: Older age (OR 1.6 per decade,
95%CI: 1.3-1.92, p < 0.001), male gender (OR 2.4, 1.6 - 3.6,
p < 0.001), and baseline cholesterol level (OR 1.04 per
mg/dL, 1.03-1.04, p < 0.001) (Table 2). In a linear regres-
sion model of cholesterol change, these 3 covariates
explained 48% of the model variability (adjusted R-
squared 0.48).
Results of Structured Chart Review Analyses
Among patients with very poor glycemic control (HbA1c
> 11.5%) at baseline, structured medical chart review
revealed that patients lost to follow up (n = 83) were more
likely to be drug (7.2% vs. 1.5%, p = 0.04) or alcohol users
Figure 1 Mean change in HbA1c between 1996 and 2006, by 
HbA1c level in 1996 (n = 1772).
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Table 1: Patient Characteristics in 1996 by cohort status (n = 4944).
All Patients Characteristics by cohort
(n = 4944) 2006 Cohort 
(n = 1772, 35.8%)
Lost to F/U 
(n = 1296 26.2%)
Died (n = 1876, 
37.9%)
P-value†
Age, years (SD) 60.0 (16.9) 58.8 (12.4) 59.7 (11.5) 70.6 (10.7) <0.001
Women 47.9% 49.7% 50.2% 44.5% 0. 001
Non-White race/ethnicity 23.4% 21.7% 35.7% 16.4% <0.001
Non-English Language 12.3% 10.2% 18.3% 10.2% <0.001
Mean HbA1c % (SD) 8.3 (1.8) 8.2 (1.7) 8.4 (1.9) 8.3 (1.8) 0.008
Mean # of HbA1c tests (SD) 2.0 (1.1) 2.1 (1.1) 1.8 (1.1) 1.9 (1.1) <0.001
Mean # of encounters (SD) 13.5 (11.8) 12.2 (10.7) 11.0 (10.4) 16.4 (13.9) <0.001
"2006 cohort" = patients with HbA1c results in both 1996 and 2006; "Lost to F/U" = patients who were lost to follow-up prior to 2006; "Died" 
= patients who died prior to 2006; SD = Standard Deviation
† P-values compare 2006 cohort (n = 1772) to lost-to-follow up cohort (n = 1549) to Died cohort (n = 1902)
Mean HbA1c and number of tests and outpatient encounters were those during the calendar year 1996.Blumenthal et al. BMC Health Services Research 2010, 10:158
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(12.1% vs. 2.9%, p = 0.02), have a language barrier (22.9%
vs. 8.7%, p = 0.05), and have no insurance or Medicaid
(40.3% vs. 26.2%, p = 0.08) compared to patients who
remained in care through to 2006 (n = 69). There were no
significant differences in BMI, location of diabetes care,
or prevalence of prescribed glycemic, blood pressure,
lipid, or psychiatric medications between these case and
control patients (data not shown).
In the nested case-control study of patients in the longi-
tudinal cohort with moderately poor control at baseline
(HbA1c 8.0-9.0%) matched by age and gender, we found
that patients whose HbA1c significantly improved (cases)
were less likely to take insulin in 1996 (40.0% vs. 66.0%, p
= 0.045), have private insurance or Medicare in 1996
(93.0% vs. 76.6%, p = 0.03), or attend a diabetes specialty
clinic (26.5% vs. 46.0%, p = 0.04 in 1996; 34.0% vs. 52.0%,
p = 0.06 in 2006) than those whose HbA1c significantly
worsened (controls). The mean weight loss (2.4 lbs vs. 5.3
lbs, p = 0.6) and mean increase in number of prescribed
medications (4.2 vs. 4.3, p = 0.8) were not significantly
different between cases and controls.
Discussion
The results of this study demonstrate that among patients
receiving clinical care in the same setting, glycemic con-
trol improved significantly between 1996 and 2006
despite the aging of the cohort and the 10-year increase
in duration of their diabetes. Improvement in lipid con-
Table 2: Baseline predictors of improved HbA1c or total cholesterol levels from 1996-2006, multivariate logistic 
regression models.
HbA1c (n = 1772) P-Value Total Cholesterol 
(n = 1172)
P-Value
Age (decade) 1.41 (1.3-1.6) <0.001 1.6 (1.3-1.9) <0.001
Male gender 1.1 (1.6 to 3.6) 0.41 2.4 (1.6 - 3.6) <0.001
English Speaking 2.1 (1.4-3.1) 0.01 1.0 (0.5 to 2.2) 0.95
1996 level 2.9 (2.6 - 3.2) (for HbA1c) <0.001 1.04 (1.03-1.04) (for total cholesterol) <0.001
This table presents the adjusted odds ratios (aOR) and 95% confidence intervals for two separate models; the HbA1c model identifies 
predictors of HbA1c improving from 1996 to 2006 after adjusting for all of the other variables; the Total cholesterol model identifies 
independent predictors of total cholesterol improving from 1996 to 2006 among patients with tests in both years (n = 1172), adjusted for the 
other variables.
Figure 2 Annual mean HbA1c from 1996-2005, comparing longitudinal (solid line, n = 1772 in all years) vs. lost to follow-up (dashed line, 
number if remaining patients for each year provided below graph).Blumenthal et al. BMC Health Services Research 2010, 10:158
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trol was even more pronounced, likely a consequence of
the greater efficacy and ease of pharmacologic treatment
for dyslipidemia relative to hyperglycemia. These results
support the conclusion that national trends towards
improved diabetes-related risk factor control are not
solely the result of "down-staging" due to greater screen-
ing and earlier diabetes diagnosis, but reflect significantly
more effective disease control for individuals living with
diabetes.
Three patient factors (older age, higher HbA1c, and
speaking English) were strongly predictive of improved
HbA1c over time, explaining roughly half the variability
in our patient population. The fact that older patients had
the most improvement suggests that the later onset phe-
notype of type 2 diabetes may be more responsive to ther-
apy. These results complement a recent study that found
among T2DM patients with Hba1c < 7.0%, older patients
were less likely to have worsening glycemic control over
the next year than younger patients [18]. Taken together,
these results suggest that more aggressive treatment
approaches may be needed for younger patients to
achieve similar success. It is perhaps not surprising that
patients with the highest HbA1c improved the most,
since they had the greatest margin for change. These
results support therapeutic optimism rather than resigna-
tion regarding patients with the poorest control. Finally,
the barrier of not speaking English highlights the critical
role of effective communication in achieving goals of care
over time. It is also possible that speaking English is a
proxy for educational level, another factor that may play a
role in achieving diabetes control.
A significant proportion of our baseline cohort (26%)
was lost to follow-up. In contrast to the loss to follow-up
associated with clinical trials, this loss is reflective of the
real world setting in which many patients in our increas-
ingly mobile society (particularly younger and poorer
patients) do not remain in the same care setting over
time. The demographic differences at baseline under-
score the fact that these patients were not lost at random.
In our structured chart review, we found that patients
with poor control who were subsequently lost to follow-
up were less likely to have private insurance and more
likely to have drug or alcohol problems than similarly
poorly controlled patients who remained in care. These
results suggest that 0.4% 10-year HbA1c improvement
may be an over-estimate, at least among patients with
poor baseline control. However, we did see (in Figure 2)
similar annual trends of HbA1c improvement among
patients ultimately lost to follow-up for the duration of
their care in the system after 1996.
The fate of our 1996 cohort also underscores the lethal-
ity of diabetes, with over one-third of our patients dying
before 2006. Patients who died were demographically dis-
tinct from our follow-up cohorts, with significantly older
mean age. For the purposes of our analysis, we did not
focus further on this group of patients, since our primary
goal was to track HbA1c changes over ten-years among
patients with a greater than 10-year life expectancy (i.e.
the population of patients most likely to benefit from
tight glycemic control). Taking the lost to follow-up and
mortality cohorts together, nearly two-thirds of patients
present in 1996 were not in our system in 2006. Thus, the
improvement in HbA1c control we found over the decade
of study may not be generalizable to the overall U.S. pop-
ulation.
The results of this study support the findings in adult
participants from the National Health and Nutrition
Examination Survey (NHANES). The earlier of the two
analyses found that glycemic control rates (HbA1c < 7%)
declined from 44.5% in NHANES III (1988-1994) to
35.8% in NHANES 1999-2000 [8] despite improvements
in treatment and understanding of the disease during this
period. These initial findings, however, were reversed in
the later study, however, suggesting that a significant
improvement in glycemic control occurred between 1999
and 2004 [7]. Our results also reveal a similar magnitude
of 10-year decline in HbA1c compared to a smaller study
conducted in our system between 1985 and 1993 in
which HbA1c's in 137 patients with T2DM declined from
8.8% to 8.4% (P = 0.09) [9]. Overall, these results demon-
strate that at the individual (rather than population) level,
patients with T2D have had an incremental decline in
HbA1c despite increasing diabetes duration over the past
two decades.
Our results must be interpreted in the context of the
study design. Because we included all eligible patients in
1996 (rather than selecting patients based on specific
HbA1c levels), our results are not biased by "regression to
the mean" seen in other studies that pre-select patients at
one of the extremes of the outcome distribution. How-
ever, clinical data for our overall patient cohort were lim-
ited to electronic medical record, laboratory, and medical
billing claims data. While this approach allowed us to
efficiently analyze one of the largest reported 10-year
"usual care" clinical cohorts for type 2 diabetes, we could
not provide specific information about actual medication
prescription patterns. To address the need for more
detailed data, we performed two structured chart
r e v i e w s .  T h e  a n a l y s i s  o f  t h e  p a t i e n t s  v e ry  p o o r l y  c o n -
trolled at baseline (HbA1c > 11.5%) provided insight into
the social barriers facing patients with poor control who
were lost to follow-up (i.e. alcohol and drug use, inade-
quate insurance, and language discordance). The com-
parison of patients who improved vs. those who
worsened over the next decade revealed higher use of
insulin in 1996 among patients who worsened, suggestingBlumenthal et al. BMC Health Services Research 2010, 10:158
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that insulin use in that earlier era is a strong marker for
greater disease severity; conversely, initiation of insulin
after 1996 may have been an important factor among
those who improved.
Conclusion
W e  f o u n d  t h a t  a m o n g  p a t i e n t s  w h o  r e m a i n e d  i n  o u r
health care system, HbA1c levels declined significantly
despite ten years of disease progression and patient aging.
Improvements in lipid control were even more pro-
nounced and provide corresponding hope that rates of
cardiovascular disease may continue to decline in this
high-risk population. Older patients with favorable 10-
year prognoses were more likely to achieve glycemic
improvement than younger patients, suggesting that the
current treatment of younger patients requires a greater
therapeutic emphasis to achieve comparable long-term
glycemic and cholesterol benefits as older patients.
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